Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014;164:536–45.

Article  PubMed  Google Scholar 

Muto R, Miyoshi H, Sato K, Furuta T, Muta H, Kawamoto K, et al. Epidemiology and secular trends of malignant lymphoma in Japan: Analysis of 9426 cases according to the World Health Organization classification. Cancer Med. 2018;7:5843–58.

Article  PubMed  PubMed Central  Google Scholar 

Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M, et al. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol. 2020;38:2849–61.

Article  CAS  PubMed  Google Scholar 

Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395:1278–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018;36:1973–80.

Article  CAS  PubMed  Google Scholar 

Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, et al. Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol. 2019;37:269–77.

Article  CAS  PubMed  Google Scholar 

Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med. 2019;380:2225–36.

Article  CAS  PubMed  Google Scholar 

Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997–1007.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018;132:2446–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, et al. NCCN Guidelines® Insights: chronic lymphocytic leukemia/small lymphocytic lymphoma, version 3.2022. J Natl Compr Canc Netw. 2022;20:622–34.

Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:23–33.

Article  CAS  PubMed  Google Scholar 

Tobinai K, Ogura M, Ishizawa K, Suzuki T, Munakata W, Uchida T, et al. Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies. Int J Hematol. 2016;103:86–94.

Article  CAS  PubMed  Google Scholar 

Izutsu K, Ando K, Ennishi D, Shibayama H, Suzumiya J, Yamamoto K, et al. Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study. Cancer Sci. 2021;112:2405–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Izutsu K, Yamamoto K, Kato K, Ishikawa T, Fukuhara N, Terui Y, et al. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Int J Hematol. 2021;113:370–80.

Article  CAS  PubMed  Google Scholar 

Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, et al. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010;116:2078–88.

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Henau O, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature. 2016;539:443–7.

Article  PubMed  PubMed Central  Google Scholar 

Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, et al. PI3Kγ is a molecular switch that controls immune suppression. Nature. 2016;539:437–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reif K, Okkenhaug K, Sasaki T, Penninger JM, Vanhaesebroeck B, Cyster JG. Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing. J Immunol. 2004;173(4):2236–40.

Article  CAS  PubMed  Google Scholar 

Faia K, White K, Proctor J, Andrade P, Pink M, Rickles R, et al. High throughput in vitro combination sensitivity screen in hematologic malignancies with the phosphoinositide-3 kinase (PI3K)-δ, γ inhibitor, duvelisib. J Clin Oncol. 2015;33(15_suppl):8559.

Izutsu K, Kato K, Kiyoi H, Yamamoto G, Shimada K, Akashi K. Phase I study of duvelisib in Japanese patients with relapsed or refractory lymphoma. Int J Hematol. 2020;112:504–9.

Article  CAS  PubMed  Google Scholar 

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.

Article  PubMed  Google Scholar 

de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012;119:2590–4.

Article  PubMed  Google Scholar 

Barrientos J, Flinn IW, Davids MS, Cashen A, Chiorazzi N, Chen SS, et al. Patterns of Duvelisib-Induced Lymphocytosis in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Including Those With High-Risk Factors Treated in the DUO Trial. Poster presented at: Society of Hematologic Oncology; September 11–14, 2019; Houston, TX.

COPIKTRA [prescribing information (United States)]. Secura Bio, Inc. Las Vegas, NV. 2021.

Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, et al. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol. 2019;37:1391–402.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hanna BS, Roessner PM, Scheffold A, Jebaraj BMC, Demerdash Y, Öztürk S, et al. PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia. Leukemia. 2019;33:1427–38.

Article  CAS  PubMed  Google Scholar 

Makita S, Hosoba R, Tobinai K. Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma. Expert Opin Drug Saf. 2020;19:1105–20.

Article  CAS  PubMed  Google Scholar 

Goto H, Izutsu K, Ennishi D, Mishima Y, Makita S, Kato K, et al. Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin’s lymphoma: an open-label, multicenter, dose-escalation phase 1 study. Int J Hematol. 2022;116(6):911–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vorobyev V, Yoon DH, Kaźmierczak M, Grosicki S, Tarella C, Genua A, et al. TEMPO: A phase 2, randomized, open-label, 2-arm study comparing two intermittent dosing schedules of duvelisib in subjects with indolent non-Hodgkin lymphoma (INHL). HemaSphere, 2022;6:(S3):1950–1.

Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, et al. Activity of the PI3K-δ, γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2018;131:888–98.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ito Y, Makita S, Tobinai K. Development of new agents for peripheral T-cell lymphoma. Expert Opin Biol Ther. 2019;19:197–209.

Article  CAS  PubMed  Google Scholar